Home › Nucleix Nabs CE Mark for Bladder EpiCheck

Nucleix Nabs CE Mark for Bladder EpiCheck

Mar 22, 2017

NEW YORK (GenomeWeb) – Nucleix said today that it has received a CE Mark for its Bladder EpiCheck test, which is intended to help urologists better monitor bladder cancer patients.

Bladder EpiCheck is a urine test that utilizes multiplexed real-time PCR to analyze a panel of 15 methylation markers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

What's Popular?

In Business News

  1. Abbott Extends Timing of Tender Offer for Alere Preferred Stock for Third Time

  2. Quidel Upgraded to Overweight by Piper Jaffray on Strength of Revised Alere Asset Acquisition

  3. Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test

  4. Tetracore Gets CE-IVD Mark for RT-PCR Thermocycler

  5. Quidel Amends Acquisition of Alere BNP Assay Business

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.